

Leon A Bach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6731929/publications.pdf>

Version: 2024-02-01

112
papers

4,064
citations

117453

34
h-index

128067

60
g-index

112
all docs

112
docs citations

112
times ranked

4672
citing authors

#	ARTICLE	IF	CITATIONS
1	Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During Journeys. <i>Diabetes Technology and Therapeutics</i> , 2022, 24, 350-356.	2.4	1
2	Response to Comment on Hamblin et al. Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitorâ€Treated Type 2 Diabetes. <i>Diabetes Care</i> 2021;44:e124â€e126. <i>Diabetes Care</i> , 2022, 45, e17-e18.	4.3	7
3	A system to detect unrecognised diabetes in a tertiary hospital. <i>Diabetic Medicine</i> , 2022, , e14841.	1.2	0
4	Adrenal gland haemorrhages following motor vehicle accident with resultant adrenal insufficiency. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2022, 2022, .	0.2	1
5	Clinical, psychological and demographic factors in a contemporary adult cohort with diabetic ketoacidosis and type 1 diabetes. <i>Internal Medicine Journal</i> , 2021, 51, 1292-1297.	0.5	7
6	Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. <i>Diabetes Technology and Therapeutics</i> , 2021, 23, 460-466.	2.4	7
7	Capillary Ketone Concentrations at the Time of Colonoscopy: A Cross-Sectional Study With Implications for SGLT2 Inhibitorâ€Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2021, 44, e124-e126.	4.3	11
8	Demographics and outcomes of inpatients with diabetic foot ulcers treated conservatively and surgically in a metropolitan hospital network. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108821.	1.1	5
9	Dexamethasone and Surgical-Site Infection. <i>New England Journal of Medicine</i> , 2021, 384, 1731-1741.	13.9	76
10	Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. <i>Diabetes Research and Clinical Practice</i> , 2021, 179, 109000.	1.1	3
11	Insulin-like growth factor-1 directly affects cardiac cellular remodelling via distinct pathways. <i>IJC Heart and Vasculature</i> , 2021, 36, 100852.	0.6	3
12	Sodiumâ€glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. <i>Medical Journal of Australia</i> , 2021, 214, 94.	0.8	1
13	Body mass index is inversely associated with capillary ketones at the time of colonoscopy: Implications for SGLT2i use. <i>Clinical Endocrinology</i> , 2021, , .	1.2	1
14	A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations. <i>Contemporary Clinical Trials</i> , 2020, 90, 105892.	0.8	29
15	Prevalence of hyperglycaemia without previously recognised diabetes mellitus in the emergency department and subsequent management: a retrospective crossâ€sectional study. <i>Internal Medicine Journal</i> , 2020, 50, 1397-1403.	0.5	5
16	Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. <i>Diabetes Care</i> , 2020, 43, 3024-3033.	4.3	85
17	Sodiumâ€glucose cotransporter type 2 inhibitors: managing the small but critical risk of diabetic ketoacidosis. <i>Medical Journal of Australia</i> , 2020, 212, 294.	0.8	3
18	Myopathy secondary to empagliflozin therapy in type 2 diabetes. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	9

#	ARTICLE	IF	CITATIONS
19	The challenges of post-bariatric surgery hypocalcaemia in pre-existing hypoparathyroidism. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	0
20	The challenges of post-bariatric surgery hypocalcaemia in pre-existing hypoparathyroidism. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	2
21	SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3077-3087.	1.8	74
22	The perioperative administration of dexamethasone and infection (PADDI) trial protocol: rationale and design of a pragmatic multicentre non-inferiority study. <i>BMJ Open</i> , 2019, 9, e030402.	0.8	8
23	What Happened to the IGF Binding Proteins?. <i>Endocrinology</i> , 2018, 159, 570-578.	1.4	36
24	Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1). <i>Diabetes</i> , 2018, 67, 755-768.	0.3	17
25	Differential expression of IGFbps in Laron syndrome-derived lymphoblastoid cell lines: Potential correlation with reduced cancer incidence. <i>Growth Hormone and IGF Research</i> , 2018, 39, 6-12.	0.5	6
26	Making sense of newer treatment options for type 2 diabetes. <i>Internal Medicine Journal</i> , 2018, 48, 762-769.	0.5	0
27	Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. <i>BMJ Open</i> , 2018, 8, e020274.	0.8	7
28	Overnight Counter-Regulatory Hormone Levels and Next Day Glycemia in Adults with Type 1 Diabetes During Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump with Low-Glucose Suspend. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 438-439.	2.4	0
29	â€œIt Is Definitely a Game Changerâ€ A Qualitative Study of Experiences with In-home Overnight Closed-Loop Technology Among Adults with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 410-416.	2.4	28
30	Poor Glycemic Control Is Associated With Decreased Survival in Lung Transplant Recipients. <i>Transplantation</i> , 2017, 101, 2200-2206.	0.5	29
31	Human monocyte-derived dendritic cells exposed to hyperthermia show a distinct gene expression profile and selective upregulation of <i>IGFBP6</i> . <i>Oncotarget</i> , 2017, 8, 60826-60840.	0.8	21
32	Current ideas on the biology of IGFBP-6: More than an IGF-II inhibitor?. <i>Growth Hormone and IGF Research</i> , 2016, 30-31, 81-86.	0.5	29
33	Glycemia, Treatment Satisfaction, Cognition, and Sleep Quality in Adults and Adolescents with Type 1 Diabetes When Using a Closed-Loop System Overnight Versus Sensor-Augmented Pump with Low-Glucose Suspend Function: A Randomized Crossover Study. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, 772-783.	2.4	77
34	Ezrin contributes to impaired podocyte migration and adhesion caused by advanced glycation end products. <i>Nephrology</i> , 2016, 21, 13-20.	0.7	6
35	Palpation thyroiditis following subtotal parathyroidectomy for hyperparathyroidism. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2016, 2016, .	0.2	5
36	Endothelial cells and the IGF system. <i>Journal of Molecular Endocrinology</i> , 2015, 54, R1-R13.	1.1	139

#	ARTICLE	IF	CITATIONS
37	Insulin-like growth factor binding proteins 4-6. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 713-722.	2.2	26
38	Differential Effects of Insulin-Like Growth Factor Binding Protein-6 (IGFBP-6) on Migration of Two Ovarian Cancer Cell Lines. Frontiers in Endocrinology, 2015, 5, 231.	1.5	18
39	Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. Journal of Surgical Research, 2015, 196, 39-48.	0.8	63
40	Recent insights into the actions of IGFBP-6. Journal of Cell Communication and Signaling, 2015, 9, 189-200.	1.8	53
41	Insulin-like Growth Factors and Kidney Disease. American Journal of Kidney Diseases, 2015, 65, 327-336.	2.1	84
42	The high burden of inpatient diabetes mellitus: the Melbourne Public Hospitals Diabetes Inpatient Audit. Medical Journal of Australia, 2014, 201, 334-338.	0.8	65
43	Diabetes Is a Major Risk Factor for Mortality After Lung Transplantation. American Journal of Transplantation, 2014, 14, 438-445.	2.6	68
44	Prevalence and Predictors of Diabetes After Lung Transplantation: A Prospective, Longitudinal Study. Diabetes Care, 2014, 37, 2919-2925.	4.3	35
45	IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 1511-1519.	1.8	35
46	Uptake of advanced glycation end products by proximal tubule epithelial cells via macropinocytosis. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2922-2932.	1.9	15
47	Targeting the <sc>AGEâ€RAGE</sc> axis improves renal function in the context of a healthy diet low in advanced glycation endâ€product content. Nephrology, 2013, 18, 47-56.	0.7	30
48	An unexpectedly high prevalence of undiagnosed diabetes in patients awaiting lung transplantation. Journal of Heart and Lung Transplantation, 2013, 32, 86-91.	0.3	9
49	Prohibitin-2 Binding Modulates Insulin-like Growth Factor-binding Protein-6 (IGFBP-6)-induced Rhabdomyosarcoma Cell Migration. Journal of Biological Chemistry, 2013, 288, 29890-29900.	1.6	47
50	Inhibition of <i>Plasmodium falciparum</i> CDPK1 by conditional expression of its J-domain demonstrates a key role in schizont development. Biochemical Journal, 2013, 452, 433-441.	1.7	51
51	Insulin-like growth factor-binding protein-6 and cancer. Clinical Science, 2013, 124, 215-229.	1.8	63
52	The insulin-like growth factor system in kidney disease and hypertension. Current Opinion in Nephrology and Hypertension, 2012, 21, 86-91.	1.0	13
53	Diabetic Nephropathy: Do Cannabinoids Contribute?. Endocrinology, 2012, 153, 1008-1009.	1.4	2
54	Advanced glycation endâ€products induce calpainâ€mediated degradation of ezrin. FEBS Journal, 2012, 279, 3240-3250.	2.2	14

#	ARTICLE	IF	CITATIONS
55	Stereotactic radiosurgery for treatment of cholangiocarcinoma: an Australian experience. <i>Internal Medicine Journal</i> , 2012, 42, 1153-1156.	0.5	20
56	IGF binding protein-6 expression in vascular endothelial cells is induced by hypoxia and plays a negative role in tumor angiogenesis. <i>International Journal of Cancer</i> , 2012, 130, 2003-2012.	2.3	50
57	Advanced glycation end products inhibit Na ⁺ K ⁺ ATPase in proximal tubule epithelial cells: Role of cytosolic phospholipase A2 α and phosphatidylinositol 4-phosphate 5-kinase β . <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010, 1803, 919-930.	1.9	17
58	Insulin-like growth factor binding protein-6 (IGFBP-6) interacts with DNA-end binding protein Ku80 to regulate cell fate. <i>Cellular Signalling</i> , 2010, 22, 1033-1043.	1.7	35
59	Crosstalk between MAP kinase pathways is involved in IGF-independent, IGFBP-6-induced Rh30 rhabdomyosarcoma cell migration. <i>Journal of Cellular Physiology</i> , 2010, 224, 636-643.	2.0	23
60	Preservation of Kidney Function with Combined Inhibition of NADPH Oxidase and Angiotensin-Converting Enzyme in Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2010, 32, 73-82.	1.4	21
61	Localization of the ezrin binding epitope for advanced glycation endproducts. <i>International Journal of Biochemistry and Cell Biology</i> , 2008, 40, 1570-1580.	1.2	6
62	Blogging During Terminal Care: Communication, Color Schemes, and Creating a Community. <i>Journal of Clinical Oncology</i> , 2008, 26, 4504-4506.	0.8	17
63	Rho Kinase Inhibition: A New Approach for Treating Diabetic Nephropathy?. <i>Diabetes</i> , 2008, 57, 532-533.	0.3	22
64	Inhibition of NADPH Oxidase Prevents Advanced Glycation End Product-Mediated Damage in Diabetic Nephropathy Through a Protein Kinase C- δ -Dependent Pathway. <i>Diabetes</i> , 2008, 57, 460-469.	0.3	317
65	Association of a Nicotinic Receptor Mutation with Reduced Height and Blunted Physostigmine-Stimulated Growth Hormone Release. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 634-637.	1.8	8
66	Outcomes for general medical inpatients with diabetes mellitus and new hyperglycaemia. <i>Medical Journal of Australia</i> , 2008, 188, 340-343.	0.8	34
67	Promotion of Cancer Cell Migration. <i>Journal of Biological Chemistry</i> , 2007, 282, 22298-22306.	1.6	59
68	Cooperativity of the N- and C-Terminal Domains of Insulin-like Growth Factor (IGF) Binding Protein 2 in IGF Binding. <i>Biochemistry</i> , 2007, 46, 13720-13732.	1.2	26
69	The N-Terminal Subdomain of Insulin-like Growth Factor (IGF) Binding Protein 6. Structure and Interaction with IGFs. <i>Biochemistry</i> , 2007, 46, 3065-3074.	1.2	20
70	Insulin-like growth factors induce apoptosis as well as proliferation in LIM 1215 colon cancer cells. <i>Journal of Cellular Biochemistry</i> , 2007, 100, 58-68.	1.2	19
71	Structure, Dynamics and Heparin Binding of the C-terminal Domain of Insulin-like Growth Factor-binding Protein-2 (IGFBP-2). <i>Journal of Molecular Biology</i> , 2006, 364, 690-704.	2.0	50
72	Advanced Glycation End Products Inhibit Tubulogenesis and Migration of Kidney Epithelial Cells in an Ezrin-Dependent Manner. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 414-421.	3.0	17

#	ARTICLE	IF	CITATIONS
73	Several Acidic Amino Acids in the N-domain of Insulin-like Growth Factor-binding Protein-5 Are Important for Its Transactivation Activity*. <i>Journal of Biological Chemistry</i> , 2006, 281, 14184-14191.	1.6	46
74	Localization of the Ezrin Binding Epitope for Glycated Proteins. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 617-624.	1.8	5
75	Effects of Advanced Glycation End Products on Ezrin-Dependent Functions in LLC-PK1 Proximal Tubule Cells. <i>Annals of the New York Academy of Sciences</i> , 2005, 1043, 609-616.	1.8	5
76	A case of mucormycosis limited to the parotid gland. <i>Head and Neck</i> , 2005, 27, 1108-1111.	0.9	14
77	Expression of the IGF System in Normal and Diabetic Transgenic (mRen-2)27 Rat Eye. , 2005, 46, 2708.		18
78	IGFBP-6 five years on; not so "forgotten"? <i>Growth Hormone and IGF Research</i> , 2005, 15, 185-192.	0.5	100
79	IGF-binding proteins "the pieces are falling into place. <i>Trends in Endocrinology and Metabolism</i> , 2005, 16, 228-234.	3.1	153
80	Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C- α -Dependent Pathway. <i>Diabetes</i> , 2004, 53, 2921-2930.	0.3	149
81	Effect of an Insulin-Like Growth Factor Binding Protein Fusion Protein on Thymidine Incorporation in Neuroblastoma and Rhabdomyosarcoma Cell Lines. <i>Endocrinology</i> , 2004, 145, 3369-3374.	1.4	6
82	C-Terminal Domain of Insulin-Like Growth Factor (IGF) Binding Protein-6: Structure and Interaction with IGF-II. <i>Molecular Endocrinology</i> , 2004, 18, 2740-2750.	3.7	44
83	Contributions of the N- and C-terminal domains of IGF binding protein-6 to IGF binding. <i>Journal of Molecular Endocrinology</i> , 2004, 33, 377-386.	1.1	34
84	C-Terminal Domain of Insulin-like Growth Factor (IGF) Binding Protein 6: Conformational Exchange and Its Correlation with IGF-II Binding. <i>Biochemistry</i> , 2004, 43, 11187-11195.	1.2	16
85	Binding site for the C-domain of insulin-like growth factor (IGF) binding protein-6 on IGF-II; implications for inhibition of IGF actions. <i>FEBS Letters</i> , 2004, 568, 19-22.	1.3	21
86	The insulin-like growth factor system: towards clinical applications. <i>Clinical Biochemist Reviews</i> , 2004, 25, 155-64.	3.3	18
87	¹ H, ¹³ C and ¹⁵ N resonance assignments of the C-terminal domain of insulin-like growth factor binding protein-6 (IGFBP-6). <i>Journal of Biomolecular NMR</i> , 2003, 25, 251-252.	1.6	5
88	Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. <i>Journal of Cellular Physiology</i> , 2003, 197, 131-138.	2.0	35
89	The Amino-terminal Domains of the Ezrin, Radixin, and Moesin (ERM) Proteins Bind Advanced Glycation End Products, an Interaction That May Play a Role in the Development of Diabetic Complications. <i>Journal of Biological Chemistry</i> , 2003, 278, 25783-25789.	1.6	56
90	Inhibition of Caco-2 cell proliferation by all-trans retinoic acid: Role of insulin-like growth factor binding protein-6. <i>Journal of Cellular Physiology</i> , 2002, 190, 92-100.	2.0	43

#	ARTICLE	IF	CITATIONS
91	Insulin-like growth factor (IGF)-binding protein-6 inhibits IGF-II-induced but not basal proliferation and adhesion of LIM 1215 colon cancer cells. <i>Molecular and Cellular Endocrinology</i> , 2001, 174, 121-127.	1.6	42
92	Overexpression of insulin-like growth factor binding protein-6 inhibits rhabdomyosarcoma growth in vivo. <i>International Journal of Cancer</i> , 2001, 94, 645-651.	2.3	58
93	Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). <i>Journal of Clinical Investigation</i> , 2001, 108, 1853-1863.	3.9	397
94	Aminoguanidine ameliorates changes in the IGF system in experimental diabetic nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 347-354.	0.4	19
95	Prevention of apoptosis by insulin-like growth factor (IGF)-I and IGF-II is differentially attenuated by IGF-binding proteins in PC12 cells. <i>Neuroscience Research Communications</i> , 2000, 27, 75-83.	0.2	8
96	O-glycosylation of insulin-like growth factor (IGF) binding protein-6 maintains high IGF-II binding affinity by decreasing binding to glycosaminoglycans and susceptibility to proteolysis. <i>FEBS Journal</i> , 2000, 267, 5378-5386.	0.2	47
97	Inhibition of CACO-2 cell proliferation by (n-3) fatty acids: possible mediation by increased secretion of insulin-like growth factor binding protein-6. <i>Nutrition Research</i> , 2000, 20, 1409-1421.	1.3	24
98	HaCaT human keratinocytes express IGF-II, IGFBP-6, and an acid-activated protease with activity against IGFBP-6. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1999, 276, E536-E542.	1.8	9
99	The N-terminal Disulfide Linkages of Human Insulin-like Growth Factor-binding Protein-6 (hIGFBP-6) and hIGFBP-1 Are Different as Determined by Mass Spectrometry. <i>Journal of Biological Chemistry</i> , 1999, 274, 14587-14594.	1.6	64
100	Localization of the Insulin-like Growth Factor System in a Rat Model of Heart Failure Induced by Myocardial Infarction. <i>Journal of Histochemistry and Cytochemistry</i> , 1999, 47, 649-659.	1.3	23
101	Induction of insulin-like growth factor binding protein expression by ICI 182,780 in a tamoxifen-resistant human breast cancer cell line. <i>Breast Cancer Research and Treatment</i> , 1999, 55, 231-242.	1.1	25
102	Differential dissociation kinetics explain the binding preference of insulin-like growth factor binding protein-6 for insulin-like growth factor-II over insulin-like growth factor-I. <i>FEBS Letters</i> , 1999, 450, 240-244.	1.3	17
103	Identification of O-Glycosylation Sites and Partial Characterization of Carbohydrate Structure and Disulfide Linkages of Human Insulin-like Growth Factor Binding Protein-6. <i>Biochemistry</i> , 1998, 37, 6572-6585.	1.2	64
104	Localization of mRNAs for insulin-like growth factor binding proteins 1 to 6 in rat kidney. <i>Kidney International</i> , 1995, 48, 402-411.	2.6	32
105	Hypertension and Cardiac Hypertrophy in Growth Hormone-Deficient Rats. <i>Clinical Science</i> , 1994, 87, 239-243.	1.8	5
106	Towards Identification of a Binding Site on Insulin-Like Growth Factor-II for IGF-Binding Proteins. <i>Advances in Experimental Medicine and Biology</i> , 1994, 343, 55-61.	0.8	4
107	Prediction of persistent microalbuminuria in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 1993, 7, 67-72.	1.2	8
108	Human insulin-like growth factor binding protein-6 is O-glycosylated. <i>Biochemical and Biophysical Research Communications</i> , 1992, 186, 301-307.	1.0	69

#	ARTICLE	IF	CITATIONS
109	Insulin-like growth factors and diabetes. <i>Diabetes/metabolism Reviews</i> , 1992, 8, 229-257.	0.2	98
110	Diabetes-related renal growth and IGF-I accumulation in castrated rats. <i>Diabetes Research and Clinical Practice</i> , 1991, 14, 15-20.	1.1	8
111	Effect of Puberty on Initial Kidney Growth and Rise in Kidney IGF-I in Diabetic Rats. <i>Diabetes</i> , 1990, 39, 557-562.	0.3	71
112	Glomerular filtration rate in early experimental diabetes. <i>The Journal of Diabetic Complications</i> , 1988, 2, 8-11.	0.2	14